Vaccine Makers Fall After RFK Jr. Says Some Shots Don't Work.

COVID-19 vaccines; DRUG approval; TREATMENT effectiveness; NOVAVAX Inc.; VACCINE manufacturing; INVESTORS; STOCK prices; UNITED States. Dept. of Health & Human Services; KENNEDY, Robert F., 1925-1968; VACCINE development

Shares of vaccine makers, including Novavax, Moderna, and Pfizer, dropped after US Health and Human Services Secretary Robert F. Kennedy Jr. expressed skepticism about the effectiveness of a specific type of Covid vaccine. Kennedy's comments raised concerns about the approval process and efficacy of these vaccines, leading to a significant decline in stock prices. Biotech investors are closely monitoring potential delays in drug approvals and the impact of Kennedy's criticisms on the FDA's decision-making process. Novavax, which is seeking full approval for its vaccine, has responded to the FDA's information requests and believes its vaccine is ready for approval. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)